[{"from": "human", "value": "Provide a brief overview of this molecule. [C][N][C][C][C@@H1][Branch1][Branch2][C][=C][C][=C][S][Ring1][Branch1][O][C][=C][C][=C][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][#Branch2]"}, {"from": "gpt", "value": "The molecule is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.\nDuloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia.\nDuloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake."}]